Heterocyclic Compounds, 2-Ring
"Heterocyclic Compounds, 2-Ring" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A class of heterocyclic compounds that include a two-ring fused structure. Both aromatic and non-aromatic ring structures are included in this category.
| Descriptor ID |
D006574
|
| MeSH Number(s) |
D03.633.100
|
| Concept/Terms |
Heterocyclic Compounds, 2-Ring- Heterocyclic Compounds, 2-Ring
- 2-Ring Heterocyclic Compounds
- Heterocyclic Compounds, 2 Ring
- Two Ring Heterocyclic Compounds
- Fused Heterocyclic Compounds, Two-Ring
- Fused Heterocyclic Compounds, Two Ring
|
Below are MeSH descriptors whose meaning is more general than "Heterocyclic Compounds, 2-Ring".
Below are MeSH descriptors whose meaning is more specific than "Heterocyclic Compounds, 2-Ring".
This graph shows the total number of publications written about "Heterocyclic Compounds, 2-Ring" by people in this website by year, and whether "Heterocyclic Compounds, 2-Ring" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 2020 | 1 | 1 | 2 |
To return to the timeline,
click here.
Below are the most recent publications written about "Heterocyclic Compounds, 2-Ring" by people in Profiles.
-
A Small Molecule with Big Impact: MRTX1133 Targets the KRASG12D Mutation in Pancreatic Cancer. Clin Cancer Res. 2024 02 16; 30(4):655-662.
-
Highlights of Studies in Cardiovascular Disease Prevention Presented at the 2020 American College of Cardiology Annual Scientific Session. Curr Atheroscler Rep. 2020 06 18; 22(8):32.
-
Epigenetic Targeting of TERT-Associated Gene Expression Signature in Human Neuroblastoma with TERT Overexpression. Cancer Res. 2020 03 01; 80(5):1024-1035.
-
The DNA Endonuclease Mus81 Regulates ZEB1 Expression and Serves as a Target of BET4 Inhibitors in Gastric Cancer. Mol Cancer Ther. 2019 08; 18(8):1439-1450.
-
BRD4 amplification facilitates an oncogenic gene expression program in high-grade serous ovarian cancer and confers sensitivity to BET inhibitors. PLoS One. 2018; 13(7):e0200826.
-
BRD4 facilitates replication stress-induced DNA damage response. Oncogene. 2018 07; 37(28):3763-3777.
-
Preclinical activity of the novel B-cell-specific Moloney murine leukemia virus integration site 1 inhibitor PTC-209 in acute myeloid leukemia: Implications for leukemia therapy. Cancer Sci. 2015 Dec; 106(12):1705-13.